Jonathan A Pachter
Overview
Explore the profile of Jonathan A Pachter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lubrano S, Cervantes-Villagrana R, Faraji F, Ramirez S, Sato K, Adame-Garcia S, et al.
Cancer Cell
. 2025 Feb;
43(3):428-445.e6.
PMID: 40020669
Widespread BRAF mutations result in persistent RAS-RAF-MEK-ERK (MAPK) signaling in melanoma. BRAF (BRAFi) and MEK (MEKi) inhibitors are approved for BRAF V600E melanomas, including those progressing on immunotherapy; however, rapid...
2.
Almazan J, Turapov T, Kircher D, Stanley K, Culver K, Medellin A, et al.
Cell Rep Med
. 2025 Feb;
6(2):101943.
PMID: 39922199
This study addresses the urgent need for effective therapies for patients with brain metastases from cutaneous melanoma, a major cause of treatment failure despite recent therapeutic advances. Utilizing mouse models...
3.
Riordan J, Nathanson T, Varzavand A, Hawkins A, Peplinski R, Hannan E, et al.
bioRxiv
. 2025 Jan;
PMID: 39764000
The Rac1 P29S hotspot mutation in cutaneous melanoma is associated with resistance to MAPK pathway inhibitors (MAPKi) and worse clinical outcomes. Moreover, activation of Rac1 guanine exchange factors (GEFs) also...
4.
Liu X, Baer J, Stone M, Knolhoff B, Hogg G, Turner M, et al.
Sci Transl Med
. 2024 Oct;
16(770):eado2402.
PMID: 39441902
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in have both been implicated as drivers...
5.
Sudhakar N, Yan L, Qiryaqos F, Engstrom L, Laguer J, Calinisan A, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1418-1430.
PMID: 38904222
KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the receptor tyrosine kinase (RTK)/mitogen-activated protein kinase (MAPK) pathway. The Son of Sevenless...
6.
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, et al.
Gynecol Oncol
. 2024 Mar;
183:133-140.
PMID: 38493021
Objectives: Low-grade-serous-ovarian-carcinoma (LGSOC) is characterized by a high recurrence rate and limited therapeutic options. About one-third of LGSOC contains mutations in MAPK pathway genes such as KRAS/NRAS/BRAF. Avutometinib is a...
7.
Arang N, Lubrano S, Ceribelli M, Rigiracciolo D, Saddawi-Konefka R, Faraji F, et al.
Cell Rep Med
. 2023 Oct;
4(11):101244.
PMID: 37858338
Uveal melanoma (UM) is the most prevalent cancer of the eye in adults, driven by activating mutation of GNAQ/GNA11; however, there are limited therapies against UM and metastatic UM (mUM)....
8.
Randall J, Evans K, Watts B, Smith C, Hughes K, Earley E, et al.
Pediatr Blood Cancer
. 2023 May;
70(8):e30398.
PMID: 37140091
Background: Acute lymphoblastic leukemia (ALL) remains one of the most common causes of cancer-related mortality in children. Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases, and aberrations in the...
9.
Chen S, Barrientos J, Ferrer G, King-Richards M, Chen Y, Ravichandran P, et al.
Clin Cancer Res
. 2023 Apr;
29(10):1984-1995.
PMID: 37071496
Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet...
10.
Till K, Abdullah M, Alnassfan T, Janet G, Marks T, Coma S, et al.
Sci Rep
. 2023 Mar;
13(1):3793.
PMID: 36882482
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that is incurable with existing therapies, and therefore presents a significant unmet clinical need. The ability of this disease to...